Home Monitoring During Chemoradiation

Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Sep 11, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Home Monitoring During Chemoradiation," is studying how to better support patients with locally advanced head and neck cancer while they undergo chemoradiotherapy, a common treatment that combines chemotherapy and radiation. The goal is to see if using home monitoring tools can help track patients' physical activity and health indicators, such as vital signs and kidney function, during and after treatment. By catching potential issues early, healthcare providers can offer timely support and improve patients' overall treatment experience.

To be eligible for this trial, participants must be at least 18 years old and have a confirmed diagnosis of head and neck cancer that requires chemoradiotherapy, specifically with a chemotherapy drug called cisplatin. Participants will need to give their consent and be able to perform simple health measurements at home. Throughout the trial, they will be closely monitored and supported, aiming to enhance their treatment journey and minimize complications. This study is currently recruiting participants, and all genders are welcome to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 at the time of signing informed consent.
• • Histologically proven head and neck carcinoma of the larynx, (oro/hypo)pharynx, oral cavity or nasopharyngeal carcinoma.
• • Indication for chemoradiotherapy, with chemotherapy that consists of weekly cisplatin.
• • Written, informed consent.
• • Ability to comply with all protocol required actions (at home measurements are done individually by the participant him- or herself).
• Exclusion Criteria:
• • - Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent or the carrying out of the measurements at home.